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Abstract 
Background. Mesenchymal stromal cells (MSCs) enhance islet function both in vitro and in 
vivo, at least in part by secreting ligands which activate islet G-Protein Coupled Receptors 
(GPCRs). We assess whether pre-treatment with a defined “cocktail” of MSC-secreted GPCR 
ligands enhances islet functional survival in vitro and improves the outcomes of islet 
transplantation in an experimental model of diabetes. Methods. Isolated islets were cultured 
for 48h with ANXA1, or SDF-1, or C3a, alone or in combination. Glucose stimulated insulin 
secretion (GSIS) and cytokine-induced apoptosis were measured immediately after the 48h 
culture period, and at 24h or 72h following removal of the ligands from the culture media.   
Islets were syngeneically transplanted underneath the kidney capsule of streptozotocin-induced 
diabetic C57BL/6 mice and blood glucose levels monitored for 28 days. Results. Preculturing 
islets with a cocktail of ANXA1/SDF-1/C3a potentiated GSIS and protected islet cells from 
cytokine-induced apoptosis in vitro. These effects were maintained for up to 72h after the 
removal of the factors from the culture medium, suggesting a sustained protection of islet graft 
functional survival during the immediate post-transplantation period.  Islets pre-treated with 
the cocktail of MSC secretory factors were more effective in reducing blood glucose in diabetic 
mice, consistent with their improved functional survival in vivo. Discussion.  Preculturing islets 
with a cocktail of MSC secretory products offers a well-defined, cell-free approach to improve 
clinical islet transplantation outcomes while avoiding many of the safety, regulatory and 
logistical hurdles of incorporating MSCs into transplantation protocols. 
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Mesenchymal stromal cell secretory factors induce sustained improvements in islet 
function pre- and post-transplantation  
 
Chloe L Rackham, Stefan Amisten, Shanta J Persaud, Aileen J F King and Peter M 
Jones 
Introduction 
Islet transplantation as a therapy for Type 1 Diabetes (T1D) is restricted by the limited 
availability of donor islets, loss of functional islets during pre-transplantation culture in vitro 
[1, 2] and further extensive loss during the immediate post-transplantation period when islet 
function and survival is compromised by the hypoxic, inflammatory host environment [3-5]. 
In experimental models a pre-transplant culture in vitro with mesenchymal stromal cells 
(MSCs) enhances β-cell secretory function in vitro [6-10], which correlates with superior graft 
function in vivo [6, 7]. The direct beneficial effects of MSCs on islet function can be attributed, 
at least in part, to paracrine effects of MSC-derived soluble mediators [11] and to MSC-
generated extracellular matrix (ECM) [12], whilst MSC effects on the host niche may improve 
the survival of islet grafts by suppressing adverse immune responses [13-17] and enhancing 
revascularisation [18-20]. Identifying MSC secretory factors which improve islet function and 
transplantation outcomes raises the possibility of harnessing the therapeutic benefits of MSCs 
in a “cell-free” strategy [11, 21], thus avoiding the logistical, safety and regulatory concerns of 
including MSCs in clinical islet transplantation protocols.   
G-protein coupled receptors (GPCRs) are the target for around 30% of known pharmaceutical 
therapeutics, and we have previously used a quantitative mRNA screening approach to identify 
over 250 different GPCRs expressed by islet cells [22] offering considerable scope for 
manipulating islet function.  We have recently applied a similar approach to  identify a panel 
of mouse and human MSC secretory products that are ligands for islet G-protein-coupled 
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receptors (GPCRs), and so have the potential to influence islet functional survival [11].   We 
have now screened these mouse [11] and human [12] MSC “secretomes” based on (i) high 
expression levels in MSC populations known to enhance islet functional survival; (ii) 
expression of their cognate receptors in mouse and human islets [22]; (iii) published evidence 
of their ability to influence islet functional survival [23-27]. These screens identified collagen-
3A1 (COL3A1); annexin A1 (ANXA1); stromal cell-derived factor-1 (SDF-1)/chemokine (C-
X-C motif) ligand (CXCL) 12; and complement component C3 as the most highly expressed 
islet GPCR ligands in mouse and human MSC populations.  The main function of COL3A is 
likely as a component of ECM, and we have recently reported that decellularized, MSC-derived 
ECM has beneficial effects on mouse and human islet function [12]. Similarly, we have 
previously reported beneficial effects of ANXA1 on mouse [11] and human [12] islet function, 
with ECM acting as a reservoir for ANXA1 [12]. In the current study we have therefore focused 
on the potential of SDF-1 and C3a to influence islet functional survival in the context of a pre-
implantation cocktail therapy. We suggest that this MSC-based, non-cellular approach will 
enable simple and defined modifications to transplantation protocols to improve the efficiency 
of clinical islet transplantation.  
 
Methods 
Islet isolation and culture   
Islets were isolated by collagenase digestion (1mg/ml; type XI; Sigma-Aldrich, Poole, UK) 
followed by density gradient separation (Histopaque-1077; Sigma-Aldrich). Briefly, 2-3ml of 
cold (4oC) collagenase solution (1mg/ml) was injected into the pancreas via the common bile 
duct following clamping at the ampulla of vater. The distended pancreas was removed and 
incubated in a water bath at 37°C for 10min.  After washing with MEM supplemented with 
10% newborn calf serum ,100U/ml penicillin and 0.1mg/ml streptomycin the pancreatic tissue 
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was vortexed and passed through a sieve to discard contaminating exocrine tissue. A 
purification gradient was generated by adding Histopaque® to the pancreatic tissue. The 
pancreatic tissue in histopaque was vortexed briefly and 10ml of MEM plus supplements added 
before centrifugation at 1900 x g, 10°C for 24min. Islets were removed from the interphase of 
the histopaque and MEM and washed three times in RPMI-1640 medium. Islets were hand-
picked into groups of 100 for preculture in RPMI supplemented with 10% Foetal Bovine Serum 
(FBS) and 100U/ml penicillin plus 0.1mg/ml streptomycin either alone, with recombinant 
human ANXA1-alone, recombinant mouse SDF-1-alone, recombinant mouse C3a-alone, or 
with combinations of these factors (R & D Systems, Abingdon, UK). Human ANXA1 has 88% 
sequence homology with mouse and rat ANXA1 [28] and we have demonstrated previously 
that human recombinant ANXA1 has similar functional effects on both human and mouse islets 
[11, 12].  
C3a and SDF-1 ELISA 
To confirm the expression of C3a and SDF-1 protein in MSC lysates and to determine whether 
C3a and SDF-1 are released into the MSC culture media (DMEM supplemented with 10% 
Foetal Bovine Serum (FBS) and 100U/ml penicillin + 0.1mg/ml streptomycin), MSCs were 
seeded into Nunclon™ 35mm petri dishes, to mimic the experimental set-up utilised for our 
direct contact islet-MSC co-culture system [6, 7]. After 2 days, MSCs from each petri dish 
were trypsinised and resuspended in ice-cold PBS supplemented with cOmplete ULTRA mini 
protease inhibitors (Roche Diagnostics, Burgess Hill, UK), then sonicated. The MSC-
conditioned media (CM) from each Petri dish was also collected and concentrated x24 using 
3,000NMWL Amicon® Ultra 2ml centrifugal filters (Merck Millipore, Middlesex, UK). 
Control samples were MSC culture media alone, which was concentrated x24. C3a and SDF-
1 were measured in MSC lysates and CM using ELISAs (Cloud-Clone Corp, Houston, USA 
and R&D Life Sciences, Abingdon, UK). 
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Islet secretory function in vitro 
Insulin secretion in vitro was assessed using static incubations of isolated islets. Islets were 
pre-incubated for 2h in RPMI containing 2mmol/L glucose. Groups of three islets were 
transferred into 1.5ml Eppendorf tubes and incubated at 37°C in a bicarbonate-buffered 
physiological salt solution containing 2mmol/L CaCl2 and 0.5mg/ml BSA [29] and either  2 or 
20mmol/L glucose. After 1h, samples of the incubation medium were taken and stored at -20°C 
until assayed for insulin content using in-house RIA [30, 31]. 
Islet Apoptosis in vitro 
To assess caspase 3/7 activity, luciferase activity dependent on caspase 3/7 – mediated 
generation of luciferase substrate was measured, according to the manufacturer’s instructions 
(Promega, Southampton, UK). Islets were precultured alone or with recombinant factors as 
described for individual experiments. For the final 20h of the culture period, half of the islets 
in each culture dish were exposed to mixed cytokines (50U/ml IL-1β, 1000U/ml IFN-γ and 
1000U/ml TNF-α (PeproTech, London, UK) and half of the islets served as controls without 
cytokines. All islets were incubated in serum-free media for this final 20h.  Islets were picked 
into groups of 5 islets/well and Caspase-Glo 3/7 reagent was added. After 1 hr, light emission 
was detected using a Turner Biosystems Veritas microplate luminometer (Promega). 
Experimental animals 
Male CD1 mice (Charles River, Margate, Kent) aged 8-12 weeks were used as islet donors for 
in vitro investigations. Male C57Bl/6 mice (Envigo, Huntingdon, UK) aged 8-12 weeks were 
used as donors and recipients for syngeneic islet transplantations. Mice were made diabetic by 
intraperitoneal streptozotocin (STZ) injection (180mg/kg; Sigma-Aldrich) one week prior to 
transplantation and those with a non-fasting blood glucose concentration of ≥20mmol/l for 
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more than three consecutive days were used as recipients. Blood glucose concentrations were 
determined using a blood glucose meter and strips (Accu-Chek; Roche, Burgess Hill, UK) with 
blood obtained from a pin prick to the tail. Where blood glucose levels exceeded the upper 
limit of the Accu-Chek meter, a stat strip express meter and strips was used (upper limit 
50mmol/L). All animal procedures were approved by our institution’s Ethics Committee and 
carried out under license, in accordance with the UK Home Office Animals (Scientific 
Procedures) Act 1986.  
Renal subcapsular islet transplantation 
Mice were transplanted with 150 islets, precultured either alone, with 5nmol/L recombinant 
ANXA1-alone, or with a cocktail of 5nmol/L ANXA1, 10nmol/L SDF-1 and 10nmol/L C3a, 
for 2 days prior to transplantation. Mice were anaesthetised with 1–5% isoflurane and 95% 
oxygen (1l/min). Carprofen (Caprieve, 4mg/k.g; Norbrook, UK) was administered 
subcutaneously prior to the surgical procedure. A lumbar incision was made, the kidney 
exposed and an incision made in the capsule. Islets that had been centrifuged into pellets in 
PE50 polyethylene tubing (Becton Dickinson, Sparks, MD, USA) were placed underneath the 
kidney capsule using a Hamilton syringe (Fisher, Pittsburg, PA, USA). Bupivacaine (Marcaine 
0.5% solution, 2mg/kg, Aspen Medical, UK) was administered subcutaneously at the 
transplantation site for post-operative analgesia. Body weight and blood glucose concentrations 
of recipient mice were monitored every day for the first week post-transplantation and every 3 
to 4 days thereafter. At the end of the 28-day monitoring period the graft-bearing kidney and 
STZ-pancreas were removed for analysis of insulin content. 
Statistical analysis 
Statistical analysis used Student’s t test or ANOVA, as appropriate. Two-way repeated-
measurement ANOVA was used with Bonferroni’s post hoc test to analyse repeated 
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measurements in the same animal at different time points. A p value of p < 0.05 was considered 
significant. All data are expressed as means ± SEM. 
Results 
Effects of SDF-1 and C3a on islet function in vitro   
Mouse adipose MSCs contained and secreted substantial amounts of both SDF-1 and C3a 
confirming that the high level of their mRNAs previously reported [11] is translated into 
secreted proteins. MSC extracts contained 7.7±1.8ng SDF-1 per 200,000 cells (n=6), and 
analysis of MSC-conditioned media showed that approximately 20% of this SDF-1 was 
released into the medium over 48h (1.7ng±0.1ng/well, n=6). MSC extracts contained 
14.1±2.3pg C3a per 200,000 cells (n=5), and over 60% of this was released into the medium 
over 48h (12.0±0.9pg/well (n=5)). Control samples of MSC culture media-alone 
(supplemented with 10% FBS and 100U/ml penicillin plus 0.1mg/ml streptomycin) contained 
comparatively low amounts of SDF-1 and C3a immunoreactivity (<0.1% of MSC- conditioned 
media).  
 
We have previously reported the expression of the GPCRs for SDF-1 and C3a on both mouse 
and human islets, these being CXCR4/CXCR7 and C3aR, respectively [27, 32]. To determine 
whether exogenous SDF-1 or C3a influence islet functional survival we measured cytokine-
induced apoptosis and glucose-stimulated insulin secretion (GSIS) in islets that had been 
precultured for 48h with nmol/L concentrations of recombinant proteins. Initial experiments 
assessed the effects of SDF-1 and C3a alone over a range of concentrations to determine which 
were effective in our in vitro screens of islet insulin secretory function and cytokine-induced 
apoptosis. The optimal concentrations were standardised for subsequent experiments 
investigating dual and triple combinations of SDF-1 and/or C3a with previously investigated 
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ANXA1. Preculturing islets for 48h with SDF-1 protected them from inflammatory cytokines 
in a dose-dependent manner, with a statistically significant effect observed at 10nmol/L SDF-
1 (Figure 1A). The protective effect of this concentration of SDF-1 was reproducible between 
different islet preparations and increasing the concentration to 20nmol/L conferred no further 
protection (Figure 1B).  Preculturing islets with SDF-1 for 48h had no influence on GSIS 
(Figure 1C), in contrast to the stimulatory effects of preculture with ANXA-1, which were 
consistently observed (Figure 1D [11]). Preculture with a dual combination of ANXA1 and 
SDF-1 did not further potentiate GSIS over effects seen with ANXA1-alone (Figure 1D). Thus, 
SDF-1 preculture protected islets from cytokine-induced apoptosis but did not influence GSIS. 
 
In contrast, preculturing islets for 48h with 10nmol/L C3a potentiated GSIS, with no further 
potentiation observed at 100nmol/L C3a (Figure 2A).  Concentrations of C3a lower than 
10nmol/L had no reproducible effect on GSIS (data not shown).  Figure 2B shows that 
preculture with 10nmol/L C3a was equally effective as preculture with ANXA1 at enhancing 
GSIS [11]. However, the effects of C3a and ANXA1 on GSIS were not additive, (Figure 2C).  
Similarly, in separate experiments, we observed no significant additive effects on GSIS of islet 
preculture with a cocktail of ANXA1/C3a/SDF-1 (islets precultured alone, 2.6±0.3ng/islet/h; 
ANXA1, 3.2±0.5ng/islet/h; ANXA1/C3a, 2.9±0.4ng/islet/h; ANXA1/C3a/SDF-1, 
3.4±0.2ng/islet/h, n=10, p > 0.05). Preculturing islets for 48h with C3a-alone had a similar 
protective influence on cytokine-induced apoptosis to that observed with ANXA1-alone 
(Figure 2D) or SDF-1-alone (Figure 1A, B), but the anti-apoptotic effects of C3a and ANXA1 
were not additive (Figure 2D). Thus, C3a preculture had similar effects to ANXA1 to enhance 
GSIS and to protect islets from cytokine-induced apoptosis but there was no additive influence 
to enhance the functional survival of islets at a time point reflecting that at which islets would 
typically be transplanted, immediately after the preculture period.  
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Sustained improvement in islet function following preculture with ANXA1, SDF-1 and/or 
C3a 
Having demonstrated that 48h preculture with ANXA1, SDF-1 and/or C3a exerted effects on 
islets which are likely to be beneficial during the immediate post-transplantation period, we 
next assessed whether the beneficial effects persisted after removal of the islet-GPCR ligands 
from the culture medium for 24-72h, since in the transplantation setting these MSC-
biotherapeutics would be present during the in vitro preculture period, but absent post-
transplantation in vivo. 
We examined the effects on GSIS and apoptosis of a 48h preculture with ANXA1, SDF-1 and 
C3a, alone or in combination, at 24h and 72h after their removal from the culture medium, to 
determine whether the beneficial effects would persist throughout a time period reflecting the 
immediate post-transplantation period (Figure 3). Preculture with ANXA1+SDF1 had 
beneficial effects on GSIS which persisted for 24h after removal of the ligands from the 
medium (Figure 3A), but this was not maintained to 72h (Figure 3B).  ANXA1+C3a preculture 
did not have sustained effects on GSIS at 24h (Figure 3A) or 72h (Figure 3B) after their 
removal from the medium. Preculturing islets with a cocktail of ANXA1+SDF-1+C3a had no 
additional effects to that of dual ANXA1+SDF-1 preculture at 24h (Figure 3A), but by 72h 
after removal of the MSC-biotherapeutics, only the cocktail of all three islet-GPCR ligands 
(ANXA1+SDF-1+C3a) caused a persistent potentiation of GSIS (Figure 3B).  Figure 3 (C, D) 
shows the sustained effects of preculture with ANXA1, SDF-1 and/or C3a on the apoptotic 
responses of islets to inflammatory cytokines. When assessed 24h after removal of the ligands 
from the medium (Figure 3C), apoptosis was reduced in islets precultured with ANXA1-alone, 
or ANXA1 in any combination with the other ligands. C3a-alone also caused a reduction in 
apoptosis but this did not reach statistical significance (Figure 3C).  However, by 72h after 
removal of the ligands, only the cocktail of ANXA1+SDF-1+C3a preculture induced a 
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sustained and significant reduction of apoptosis when the islets were exposed to inflammatory 
cytokines (Figure 3D). Thus, preculture of islets with a cocktail of MSC secretory factors 
influences islet insulin secretory and apoptotic responses for up to 72h after their exposure.  
Effects of preculture on in vivo function of transplanted islets  
Preculturing islets for 48h with a cocktail of ANXA1, SDF-1 and C3a immediately prior to 
their transplantation into severely hyperglycaemic mice had modest effects on their ability to 
regulate blood glucose in vivo, as shown in Figure 4. Thus, the average blood glucose 
concentrations of mice transplanted with ANXA1/SDF-1/C3a precultured islets were 
consistently lower than those of mice transplanted with islets precultured alone (Figure 4A), 
with a significant decrease in AUC (Figure 4B). We have previously reported a modest effect 
of preculture with ANXA1-alone on islet graft function [11] and we observed a similar effect 
in the current study, where mice receiving islets precultured with ANXA1-alone had lower 
blood glucose than mice transplanted with islets precultured alone at all time points, although 
this did not achieve statistical significance (Figure 4A). Notably, the average blood glucose 
concentrations of mice transplanted with ANXA1+SDF-1+C3a precultured islets were 
consistently lower than those of mice transplanted with ANXA1-alone precultured islets 
(Figure 4A, B). In terms of reversing hyperglycaemia (i.e. non-fasting blood glucose 
concentrations ≤ 11.1 mmol/L for at least two consecutive readings), by the end of the 28-day 
study this was achieved in 2/8 mice transplanted with ANXA1+SDF-1+C3a precultured islets, 
1/9 mice transplanted with ANXA1-alone precultured islets, and 0/7 of mice transplanted with 
islets precultured alone. 
At the end of the 28-day study there was considerable variation in the graft insulin content, 
ranging from 1.0-2.2μg, 0.7-6.9μg and 0.9-5.7μg in mice transplanted with control islets, 
ANXA1-pre-treated islets, and ANXA1/SDF-1/C3a-pre-treated islets, respectively. The mean 
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insulin content was approximately 30% higher in grafts consisting of ANXA1-alone 
precultured islets and 50% higher in grafts consisting of ANXA1/SDF-1/C3a precultured islets, 
compared to those consisting of islets precultured alone, although this was not statistically 
significant (1.51+0.17μg/graft vs. 1.98+0.63μg/graft vs. 2.27+0.77μg/graft, islet-alone vs. 
ANXA1-alone vs. ANXA1/SDF-1/C3a precultured islets, respectively). The insulin content of 
the pancreas in all STZ-treated mice was approximately ten times lower than that of the 
subcapsular islet grafts. There was no difference in the STZ-pancreas insulin content for mice 
transplanted with islets precultured alone, with ANXA1-alone, or with the cocktail of MSC-
derived biotherapeutics (0.22±0.02μg vs. 0.21±0.03μg vs. 0.21±0.03μg, p > 0.05 n=8, One-
Way ANOVA with Dunnet’s post hoc test). 
Discussion 
Recent experimental studies have demonstrated the beneficial effects that MSCs exert directly 
on islet function and on the outcomes of islet transplantation [6-9], but these observations have 
yet to translate into improvements in human islet function for clinical islet transplantation in 
T1D. One reason for this is that currently human islets are almost exclusively implanted via 
the hepatic portal vein [33], which does not facilitate co-engraftment of islets and MSCs 
because their different sizes influence where they will lodge in the circulation. Thus, after 
intraportal delivery the islets (100-200µm diameter) lodge in the hepatic microvessels, while 
the much smaller MSCs will most likely pass through the microvessels to lodge in capillary 
beds of the  liver  or other organs [34].  An alternative strategy to co-transplanting islets and 
MSCs is a pre-transplantation co-culture period in vitro, and studies in rodent models have 
reported enhanced islet function [8, 9] which correlates with improved transplantation 
outcomes [6, 7]. However, there are also impediments to applying these observations to clinical 
islet transplantation protocols. For example, scaling up co-culture systems to accommodate the 
large numbers of human islets and MSCs required for clinical transplantation is technically 
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challenging. In addition, the inherent heterogeneity in different MSC populations [35] presents 
problems in standardisation. However, the recent demonstration that some of the beneficial 
effects of MSCs on islet function are mediated through MSC secretory products [11, 12] offers 
the potential of using these molecules in defined protocols to improve islet functional survival, 
thus avoiding the logistical, safety and regulatory problems of including MSCs in clinical islet 
transplantation protocols.  The current study therefore focused on defining a cocktail of MSC-
derived secretory molecules with the potential to improve the functional survival of islet grafts. 
We have previously reported that the most highly expressed of these molecules, Annexin A1 
(ANXA1), mimicked the beneficial effects of MSC preculture on β-cell insulin secretory 
function in vitro, but had only modest effects on the capacity of an islet graft to regulate blood 
glucose in hyperglycaemic mice, suggesting that additional MSC secretory products factors are 
needed to fully mimic the beneficial effect of MSCs in vivo [11]. In the present study we have 
therefore investigated the effects of other MSC-secreted islet GPCR ligands, alone or in 
combination with ANXA1, on the function and survival of islets during an in vitro preculture 
period, and on subsequent transplantation outcomes.   
SDF-1 is a peptide chemokine initially identified in bone marrow stromal cells, but now known 
to be expressed in stromal tissues of many organs [36], including the microvascular 
endothelium of pancreatic islets [25]. We here demonstrate that MSC populations which have 
beneficial effects on islet functional survival synthesise and secrete substantial amounts of 
SDF-1. Our observation that pre-incubation with SDF-1 protected isolated islets from 
subsequent cytokine-induced apoptosis is consistent with previous studies demonstrating that 
SDF-1 has an important role in cell survival responses. SDF-1 is upregulated in stromal tissues 
and β-cells in response to injury [24] suggesting an endogenous pro-survival function within 
islets. Similarly, exogenous SDF-1 reduced apoptosis in the INS-1 β-cell line [37], while 
experimental overexpression of SDF-1 in β-cells protected them from STZ- and thapsigargin-
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induced apoptosis [24]. However, exposure to SDF-1 in our pre-treatment protocol had no 
detectable effect on GSIS, in direct contrast to the beneficial effects of ANXA1 on GSIS in this 
study, and in our previous studies [11]. These observations suggest that SDF-1 and ANXA1 
influence β-cell functional survival via distinct mechanisms, and thus validate the inclusion of 
both molecules in an islet pre-treatment regimen. 
C3, a key protein in the complement system, is converted by proteolytic cleavage to 
biologically active products, including C3a. The adipokine adipsin (complement factor D) 
improves islet β-cell function by increasing the conversion of circulating C3 into C3a, which 
has acute effects to increase islet oxygen consumption rate [26], and is a potent stimulator of 
insulin secretion in mouse [26] and human islets [27]. We here demonstrate that MSCs secrete 
C3a into the culture media, and that preculture with exogenous C3a has persistent effects on 
islet function, consistent with C3a being a soluble mediator through which MSCs influence 
islet function.  The effects of C3a pre-treatment on islet functional survival were similar to 
those of ANXA1, both enhancing GSIS and reducing cytokine-induced apoptosis, and the 
effects of C3a and ANXA1 were not additive on either functional end-point. The lack of 
additive effects may suggest similar mechanism(s) through which both molecules influence 
islet cell function, or it may be a consequence of the endpoints for assessing islet function in 
vitro. Thus, preculture with either molecule essentially suppressed cytokine-induced apoptosis, 
such that additive effects would not be readily detected in this in vitro model. Similarly, if 
preculture with either molecule maintains optimal GSIS at the 48h time-point immediately 
following the preculture period, it is unlikely that additive effects would be detected. 
Nonetheless, the demonstrable effects of C3a preculture on islet secretory function and survival 
validate its inclusion in an islet pre-treatment regimen. 
It is perhaps not surprising that exposure to biologically active molecules secreted by MSCs 
influenced the ability of islet β-cells to maintain insulin secretion and resist inflammatory 
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cytokines, since the molecules were selected on the basis of their receptors being expressed by 
islet cells [22]. However, these effects were consistently observed in the subsequent absence 
of the exogenous molecules of interest after the pre-incubation period, and the current study 
has also demonstrated that some of these potentially beneficial effects persisted for at least 72h 
after the pre-incubation period. Thus, pre-treatment of isolated islets with ANXA1-alone, or in 
combination with SDF-1 was effective for up 24h after exposure, although only the cocktail of 
all three molecules endowed persistent beneficial effects on GSIS and apoptosis up to 72h after 
withdrawal of the ligands.  These in vitro observations therefore suggest that a 48h pre-
incubation with the cocktail of molecules can confer on islets improved GSIS and resistance to 
inflammatory cytokines over the immediate post-transplantation period when they are most at 
risk of functional failure. In accordance with this, our in vivo studies demonstrated that islets 
precultured with the cocktail of ANXA1, SDF-1 and C3a were more effective than untreated 
islets or those precultured with ANXA1-alone at reducing hyperglycaemia in STZ-treated graft 
recipients. The lower blood glucose levels observed in recipients of cocktail-treated islets most 
likely reflects a combination of their enhanced GSIS and their resistance to inflammatory 
stresses in the host transplantation niche, as indicated by the maintained graft insulin content 
at 28-days post-transplantation in cocktail-treated islets. These observations are important 
because a large proportion of a clinical islet graft (50-80%) is functionally compromised in the 
immediate (24-72h) post-transplantation period [4], most likely because of deleterious 
responses of transplanted islet cells to an inflammatory and hypoxic host environment [3-5]. 
Strategies which limit the post-transplantation loss of islets are therefore likely to improve the 
outcome of individual grafts, and also enable the limited pool of donor islets to treat more 
people with T1DM  by avoiding the current clinical practice of administering multiple grafts 
to achieve normoglycemia [38].  The current study focused on ligands for islet cell GPCRs but 
MSCs also secrete a range of ligands which act through non-GPCRs, raising the real possibility 
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that extending our screening to all β-cell surface receptors may further enhance the efficacy of 
this therapeutic approach to islet transplantation. 
In summary, we have identified a cocktail of MSC secretory products which has the potential 
to maintain functional β-cell mass during the in vitro pre-culture period and to support islet 
functional survival after transplantation. We suggest that pre-treatment with this cocktail of 
ANXA1, SDF-1 and C3a offers a well-defined, cell-free approach [21] to improve clinical islet 
transplantation outcomes while avoiding many of the safety, regulatory and logistical hurdles 
of incorporating MSCs into transplantation protocols.  
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Figure Legends 
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Figure 1: In vitro function of islets precultured with exogenous Stromal Cell Derived 
Factor-1. A. Dose-dependent protection from cytokine-induced apoptosis following 48h 
preculture with SDF-1 and the subsequent presence of SDF-1 during the final 20h cytokine 
incubation. 8-12 replicates of 5 islets per well in each culture group assayed, *p < 0.01 vs. 
islets precultured alone in the presence of cytokines for the final 20h of the 3-day culture period 
B. Dose-dependent protection from cytokine-induced apoptosis following preculture with 
SDF-1, as in (A); an effect that plateaus at 10nmol/L SDF-1. C, D. Insulin release at 2mmol/L 
and 20mmol/L glucose of 30 replicates of 3 mouse islets per Eppendorf tube; (C) precultured 
either alone, with 10nmol/L SDF-1, or with 20nmol/L SDF-1 for 48h followed by subsequent 
GSIS assays in the absence of exogenous SDF-1 and; (D) precultured either alone, with 
5nmol/L ANXA1-alone, with 10nmol/L SDF-1-alone, or with a dual combination of 5nmol/L 
ANXA1 and 10nmol/L SDF-1, for 48h followed by subsequent GSIS assays in the absence of 
exogenous ANXA1 and/or SDF-1 *p < 0.01 vs. islets precultured alone at the same glucose 
concentration. The p values (A-D) were calculated using two-way ANOVA Bonferonni’s post 
hoc test. Data were consistent between three separate islet preparations. 
Figure 2: In vitro function of islets precultured with exogenous complement component 
C3a A, B. Insulin release at 2mmol/L and 20mmol/L glucose of 10-20 replicates of 3 mouse 
islets per Eppendorf tube; (A) precultured either alone, with 10nmol/L C3a-alone or with 
100nmol/L C3a-alone, for 48h followed by subsequent GSIS assays in the absence of 
exogenous C3a; (B) precultured either alone, with 5nmol/L ANXA1-alone or with 10nmol/L 
C3a-alone for 48h followed by subsequent GSIS assays in the absence of exogenous C3a or 
ANXA1; (C) precultured either alone, with 5nmol/L ANXA1-alone or with a dual combination 
of 5nmol/L ANXA1 and 10nmol/L C3a for 48h followed by subsequent GSIS assays in the 
absence of exogenous C3a and/or ANXA1, p < 0.05 vs. islets precultured alone at the same 
glucose concentration. D. Protection from cytokine-induced apoptosis following a 48h 
21 
 
preculture with 5nmol/L ANXA1-alone, 10nmol/L C3a-alone or a dual combination of 
5nmol/L ANXA1 and 10nmol/L C3a, and the subsequent presence of specified MSC-
biotherapeutics during the final 20h cytokine incubation. 8-12 replicates of 5 islets per well in 
each culture group assayed, *p < 0.05 vs. islets precultured alone in the presence of cytokines 
for the final 20h of the 3-day culture period. The p values (A-D) were calculated using two-
way ANOVA Bonferonni’s post hoc test. 
Figure 3: Preculturing islets with a cocktail of MSC secretory factors ensures sustained 
improvements to islet insulin secretory function and protection from cytokine-induced 
apoptosis. A, B: Insulin release at 2mmol/L and 20mmol/L glucose of 30 replicates of 3 mouse 
islets per Eppendorf tube, precultured alone, with 5nmol/L ANXA1-alone, with 5nmol/L 
ANXA1 and 10nmol/L SDF-1, with 5nmol/L ANXA1 and 10nmol/L C3a, or with a cocktail 
of 5nmol/L ANXA1, 10nmol/L SDF-1 and 10nmol/L C3a, for 48h, before removal of the 
MSC-derived biotherapeutics for 1 day (A) or 3 days (B), * p < 0.05 and ** p < 0.01 vs. islets 
cultured alone at the same glucose concentration. C, D: Protection of islets from cytokine-
induced apoptosis after preculture with MSC-derived biotherapeutics either alone, in dual 
combination, or a cocktail of all three factors (as of legend) for 48h, before removal of the 
MSC-derived biotherapeutics for 1 day (C) or 3 days (D), 8-12 replicates of 5 islets per well 
were assayed, * p < 0.05 and ** p < 0.01 vs. islets cultured alone with cytokines, + p < 0.05 
vs. islets cultured alone without cytokines. The p values (A-D) were calculated using two-way 
ANOVA with Bonferroni post hoc test.  
Figure 4: In vivo function of islets precultured alone, with ANXA1-alone, or with a 
cocktail of MSC secretory factors. A. Average blood glucose concentrations of STZ-diabetic 
mice transplanted with 150 islets precultured for 48h either alone, with ANXA1-alone, or with 
a cocktail of ANXA1/SDF-1/C3a, *p < 0.05 vs. mice transplanted with islets precultured alone 
(repeated-measurements ANOVA with Bonferroni post hoc test, n=7-9). B. Area under the 
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curve (AUC) of STZ-diabetic mice transplanted with 150 islets precultured for 48h either 
alone, with ANXA1-alone, or with a cocktail of ANXA1/SDF-1/C3a, *p < 0.05 vs. mice 
transplanted with islets precultured alone (One-way ANOVA with Dunn’s post hoc test, n=7-
9). 
